Skip to main content

Allerest Eye Drops Disease Interactions

There are 4 disease interactions with Allerest Eye Drops (naphazoline ophthalmic).

Major

Ophthalmic sympathomimetics (applies to Allerest Eye Drops) narrow angles

Major Potential Hazard, High plausibility. Applicable conditions: Glaucoma (Narrow Angle)

The use of nonspecific ophthalmic sympathomimetic agents is contraindicated in patients with narrow-angle glaucoma or anatomically narrow angles. These agents stimulate both alpha-1 and alpha-2 adrenergic receptors, thus topical administration can induce transient mydriasis. In patients with narrow angles, pupillary dilation can provoke an acute attack of angle-closure glaucoma. If possible, these agents (except for phenylephrine 2.5% or 10%) should also be avoided in patients with other forms of glaucoma, since mydriasis may occasionally increase intraocular pressure.

References

  1. "Product Information. Collyrium Fresh (boric acid ophthalmic)." Wyeth-Ayerst Laboratories
  2. "Product Information. Naphcon (naphazoline ophthalmic)." Alcon Laboratories Inc PROD (2001):
  3. "Product Information. Ocuclear (oxymetazoline ophthalmic)." Schering-Plough PROD (2001):
  4. "Product Information. Neo-Synephrine (phenylephrine ophthalmic)." Sanofi Winthrop Pharmaceuticals PROD (2001):
View all 4 references
Moderate

Topical sympathomimetics (applies to Allerest Eye Drops) BPH

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Benign Prostatic Hyperplasia, Prostate Tumor

Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In patients with prostate enlargement, urinary difficulty may develop or worsen due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with topical sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate. It is important that the recommended dosages of the individual products not be exceeded.

References

  1. Lansche RK "Systemic reactions to topical epinephrine and phenylephrine." Am J Ophthalmol 61 (1966): 95-8
  2. Ellis PP "Systemic reactions to topical therapy." Int Ophthalmol Clin 11 (1971): 1-11
  3. "Product Information. Tyzine Nasal (tetrahydrozoline nasal)." Kenwood Laboratories PROD
  4. "Product Information. Collyrium Fresh (boric acid ophthalmic)." Wyeth-Ayerst Laboratories
  5. "Product Information. Naphcon (naphazoline ophthalmic)." Alcon Laboratories Inc PROD (2001):
  6. "Product Information. Ocuclear (oxymetazoline ophthalmic)." Schering-Plough PROD (2001):
  7. "Product Information. Neo-Synephrine (phenylephrine ophthalmic)." Sanofi Winthrop Pharmaceuticals PROD (2001):
  8. "Product Information. Afrin (oxymetazoline nasal)." Schering-Plough PROD (2001):
  9. "Product Information. Otrivin (xylometazoline nasal)." Novartis Pharmaceuticals PROD
  10. "Product Information. Privine (naphazoline nasal)." Novartis Consumer Health PROD (2001):
  11. "Product Information. Neo-Synephrine Nasal (phenylephrine nasal)." Southwood Pharmaceuticals Inc PROD (2001):
  12. "Product Information. Vapor Inhaler (levmetamfetamine nasal)." Procter and Gamble Pharmaceuticals PROD
  13. "Product Information. Benzedrex (propylhexedrine nasal)." Menley and James Laboratories Inc PROD (2001):
  14. "Product Information. Pretz-D (ephedrine nasal)." Parnell Pharmaceuticals Inc PROD (2001):
View all 14 references
Moderate

Topical sympathomimetics (applies to Allerest Eye Drops) cardiovascular

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease, Cerebrovascular Insufficiency, Hyperthyroidism, Corneal Abrasion

Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta-1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, and coronary occlusion have been reported rarely during the use of ophthalmic and nasal sympathomimetic agents, but may be more likely if the corneal epithelium is damaged or if an excessive amount of drug is swallowed during nasal administration. Therapy with topical sympathomimetic agents should be administered cautiously in patients with corneal abrasion, sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders, especially coronary insufficiency, cardiac arrhythmia, or hypertension. The potent ophthalmic formulations (e.g., phenylephrine 2.5% or 10%) that are used for diagnostic and pre-surgical purposes should not be used in such patients. For other preparations, it is important that the recommended dosages of the individual products not be exceeded.

References

  1. Lansche RK "Systemic reactions to topical epinephrine and phenylephrine." Am J Ophthalmol 61 (1966): 95-8
  2. Ellis PP "Systemic reactions to topical therapy." Int Ophthalmol Clin 11 (1971): 1-11
  3. "Product Information. Tyzine Nasal (tetrahydrozoline nasal)." Kenwood Laboratories PROD
  4. "Product Information. Collyrium Fresh (boric acid ophthalmic)." Wyeth-Ayerst Laboratories
  5. "Product Information. Naphcon (naphazoline ophthalmic)." Alcon Laboratories Inc PROD (2001):
  6. "Product Information. Ocuclear (oxymetazoline ophthalmic)." Schering-Plough PROD (2001):
  7. "Product Information. Neo-Synephrine (phenylephrine ophthalmic)." Sanofi Winthrop Pharmaceuticals PROD (2001):
  8. "Product Information. Afrin (oxymetazoline nasal)." Schering-Plough PROD (2001):
  9. "Product Information. Otrivin (xylometazoline nasal)." Novartis Pharmaceuticals PROD
  10. "Product Information. Privine (naphazoline nasal)." Novartis Consumer Health PROD (2001):
  11. "Product Information. Neo-Synephrine Nasal (phenylephrine nasal)." Southwood Pharmaceuticals Inc PROD (2001):
  12. "Product Information. Vapor Inhaler (levmetamfetamine nasal)." Procter and Gamble Pharmaceuticals PROD
  13. "Product Information. Benzedrex (propylhexedrine nasal)." Menley and James Laboratories Inc PROD (2001):
  14. "Product Information. Pretz-D (ephedrine nasal)." Parnell Pharmaceuticals Inc PROD (2001):
View all 14 references
Moderate

Topical sympathomimetics (applies to Allerest Eye Drops) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Topically applied sympathomimetic agents are systemically absorbed, particularly during prolonged or indiscriminate use. Slight increases in blood glucose concentrations may occur with the use of these drugs. Therapy with topical sympathomimetic agents should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate. It is important that the recommended dosages of the individual products not be exceeded.

References

  1. Lansche RK "Systemic reactions to topical epinephrine and phenylephrine." Am J Ophthalmol 61 (1966): 95-8
  2. Ellis PP "Systemic reactions to topical therapy." Int Ophthalmol Clin 11 (1971): 1-11
  3. "Product Information. Tyzine Nasal (tetrahydrozoline nasal)." Kenwood Laboratories PROD
  4. "Product Information. Collyrium Fresh (boric acid ophthalmic)." Wyeth-Ayerst Laboratories
  5. "Product Information. Naphcon (naphazoline ophthalmic)." Alcon Laboratories Inc PROD (2001):
  6. "Product Information. Ocuclear (oxymetazoline ophthalmic)." Schering-Plough PROD (2001):
  7. "Product Information. Neo-Synephrine (phenylephrine ophthalmic)." Sanofi Winthrop Pharmaceuticals PROD (2001):
  8. "Product Information. Afrin (oxymetazoline nasal)." Schering-Plough PROD (2001):
  9. "Product Information. Otrivin (xylometazoline nasal)." Novartis Pharmaceuticals PROD
  10. "Product Information. Privine (naphazoline nasal)." Novartis Consumer Health PROD (2001):
  11. "Product Information. Neo-Synephrine Nasal (phenylephrine nasal)." Southwood Pharmaceuticals Inc PROD (2001):
  12. "Product Information. Vapor Inhaler (levmetamfetamine nasal)." Procter and Gamble Pharmaceuticals PROD
  13. "Product Information. Benzedrex (propylhexedrine nasal)." Menley and James Laboratories Inc PROD (2001):
  14. "Product Information. Pretz-D (ephedrine nasal)." Parnell Pharmaceuticals Inc PROD (2001):
View all 14 references

Allerest Eye Drops drug interactions

There are 49 drug interactions with Allerest Eye Drops (naphazoline ophthalmic).


Report options

Loading...
QR code containing a link to this page

More about Allerest Eye Drops (naphazoline ophthalmic)

Related treatment guides

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.